This ESH update was deemed necessary with the publication of new results of sham-controlled randomized blinded prospective trials with renal denervation (RDN). Proof of concept studies and first randomized trials (some were sham-controlled) displayed discrepant results about the efficacy of RDN. Three sham-controlled randomized trials of the 2.0 generation yielded now similarity in the average blood pressure decrease following RDN. Reduction of ambulatory blood pressure was approximately 5 to 7 mmHg and of office blood pressure 10 mmHg. Such a decrease in blood pressure by pharmacologic therapy has been found to be associated with lower incidence of cardiovascular events in particular with respect to heart failure and stroke by roughly 25%. Nevertheless, some questions about renal denervation are unanswered. The heterogeneity of the blood pressure-lowering response point to the clinical need to identify predictors for efficacy, and questions on long-term safety could not have been answered due to the short duration of the sham-controlled randomized clinical trials.

Schmieder, R., Mahfoud, F., Azizi, M., Pathak, A., Dimitriadis, K., Kroon, A., et al. (2018). European society of hypertension position paper on renal denervation 2018. JOURNAL OF HYPERTENSION, 36(10), 2042-2048 [10.1097/HJH.0000000000001858].

European society of hypertension position paper on renal denervation 2018

Mancia G.;
2018

Abstract

This ESH update was deemed necessary with the publication of new results of sham-controlled randomized blinded prospective trials with renal denervation (RDN). Proof of concept studies and first randomized trials (some were sham-controlled) displayed discrepant results about the efficacy of RDN. Three sham-controlled randomized trials of the 2.0 generation yielded now similarity in the average blood pressure decrease following RDN. Reduction of ambulatory blood pressure was approximately 5 to 7 mmHg and of office blood pressure 10 mmHg. Such a decrease in blood pressure by pharmacologic therapy has been found to be associated with lower incidence of cardiovascular events in particular with respect to heart failure and stroke by roughly 25%. Nevertheless, some questions about renal denervation are unanswered. The heterogeneity of the blood pressure-lowering response point to the clinical need to identify predictors for efficacy, and questions on long-term safety could not have been answered due to the short duration of the sham-controlled randomized clinical trials.
Articolo in rivista - Articolo scientifico
Hypertension; Randomized controlled trial; Renal denervation; Renal nerves;
English
2018
36
10
2042
2048
none
Schmieder, R., Mahfoud, F., Azizi, M., Pathak, A., Dimitriadis, K., Kroon, A., et al. (2018). European society of hypertension position paper on renal denervation 2018. JOURNAL OF HYPERTENSION, 36(10), 2042-2048 [10.1097/HJH.0000000000001858].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/434051
Citazioni
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 35
Social impact